Characterizing Skin Microbiome Change in Atopic Dermatitis
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Atopic dermatitis (AD), also known as eczema, is an inflammatory disease of the skin
affecting a large proportion of the pediatric and adult patient population. Chronic itching
and eczematous lesions lead to a high burden of disease and associated patient morbidity with
higher infection rates, emotional stress and associated psychological disease. The microbiome
community contributes to human health through several mechanisms. Current research suggests
that derangements in the normal microbiota may lead to inflammatory bowel disease, allergy,
and metabolic syndromes. Specific to dermatology, new literature has demonstrated that
changes in the microbiome may play a role in the development of atopic dermatitis.
With this study, the investigators hope to characterize the baseline atopic dermatitis skin
microbiome and monitor the evolution of the participants skin microbiome during and after
treatment with anti-inflammatory topical medications, specifically the Food and Drug
Administration (FDA)-approved phosphodiesterase inhibitor, crisaborole ointment 2% (Eucrisa).